DMIIU

Drugs Made In America Acquisition II Corp Unit

DMIIU

Positive

Neutral

Negative

Sentiment 3-Months

Positive

Neutral 100%

Negative

U.S. IPO Weekly Recap: One Small Debut As More Names Join The Pipeline

One IPO and four SPACS debuted this week. Six IPOs and three SPACs submitted initial filings. Two sizable deals are currently scheduled to price in the week ahead as the 3Q IPO market comes to a close.

U.S. IPO Weekly Recap: One Small Debut As More Names Join The Pipeline

Drugs Made In America Acquisition II Corp. Announces Closing of $500,000,000 Initial Public Offering

Fort Lauderdale, FL, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) (the “Company”) today announced that it closed its initial public offering of 50,000,000 units at $10.00 per unit. The gross proceeds from the offering were $500 million before deducting underwriting discounts and offering expenses. The units began trading on The Nasdaq Global Market ("Nasdaq") under the ticker symbol "DMIIU” on September 25, 2025.

Drugs Made In America Acquisition II Corp. Announces Closing of $500,000,000 Initial Public Offering

See News Rankings